EPAC1 ACTIVATORS AS HIV LATENCY REVERSAL AGENTS (LRA)

摘要

The invention relates generally to novel EPAC1 activators, such as Formula I and the preparation thereof as well as the use of EPAC1 activators as human immunodeficiency virus (HIV) latency reversal agents (LRAs).;